Logo

Caliper Cuts '06 Outlook as SEC Review Delays Xenogen Acquisition

Jul 13, 2006
NEW YORK (GenomeWeb News) - Caliper Life Sciences lowered its previously announced financial outlook for the year due to an SEC review of the company's plan to buy Xenogen, which delayed the acquisition, the company said today.
 
Caliper revised its 2006 revenue forecast from between $120 million and $128 million to between $110 million and $118 million. A Caliper spokeswoman said that the US Securities and Exchange Commission selected the filing for review, which set the acquisition back by three months.
 
As GenomeWeb News reported in February, Caliper announced it would buy Xenogen for $80 million in stock and expected the transaction to close in the second quarter.
 
The delay required the company to adjust its projected revenues, which originally included Xenogen's second-quarter revenues, the spokeswoman said.  
 
The companies said they plan to hold a stockholder meeting on Aug. 9 to approve the acquisition.

Breaking News
The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.